All In Biotech

NDA 208223 · Tonix Meds

Zembrace Symtouch (Autoinjector)

Sumatriptan Succinate · Subcutaneous

Last checked: Nov 20, 2026Latest source record: Jun 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jan 28, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

113

33 Phase 3, 5 recruiting

FAERS reports

7,926

3,886 serious, 216 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 28, 2025.

ZEMBRACE SymTouch is indicated for the acute treatment of migraine with or without aura in adults. ZEMBRACE SymTouch is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established. ( 1 ) Not indicated for the prophylactic therapy of migraine. ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with ZEMBRACE SymTouch, reconsider the diagnosis before ZEMBRACE SymTouch is administered to treat any subsequent attacks. ZEMBRACE SymTouch injection is not indicated for the prevention of migraine attacks.

Mechanism: Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 10, 2019 Supplement 5 · Efficacy LabelLetter
  • Jan 28, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • ZEMBRACE SYMTOUCH (AUTOINJECTOR) · SUMATRIPTAN SUCCINATE EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sumatriptan" as an intervention, any sponsor and status, largest first.

All 113 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,185
  • headache793
  • migraine664
  • nausea591
  • product dose omission issue574
  • fatigue503
  • off label use456
  • product quality issue433
  • device malfunction404
  • pain383
  • dizziness371
  • product complaint349

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200447
200554
200657
200799
200881
2009175
2010425
2011296
2012195
2013148
2014170
2015213
2016444
2017294
2018377
2019387
2020565
2021524
2022558
2023695
2024664
2025602
2026856

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 589 on PubMed

Sponsor: Tonix Meds

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.